1 / 26

Who we are?

Who we are?. Team of specialised experts All services for whole Europe in one place EU regulatory knowledge and strategies MA holding and support EU/ local RA and PHV contact. Our Services. Continuous support and updates depending on EU legislation Regulatory services

gayora
Download Presentation

Who we are?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Whowe are? • Team ofspecialisedexperts • AllservicesforwholeEurope in oneplace • EU regulatoryknowledgeandstrategies • MA holding and support • EU/local RA and PHV contact

  2. Our Services • Continuous support andupdatesdepending on EU legislation • Regulatoryservices • Medicinalproducts, medicaldevices • Cosmetics, foodsupplements • Veterinaryproducts • Education + trainings • ClinicalTrials • PASS - Post-AuthorisationSafetyStudies • Marketing + sales • Import/Distribution • Marketing

  3. RA Services = Regulatory House

  4. Our Services – Key Features • Partner/Products/Concept analysis • Identification of key issues and risks of market entry • Elaborating of possible scenarios and strategy alternatives • Quantification of alternatives • Value, Time, Risks • Evaluation of influence on • Product definition • Registration strategy • Pricing • Reimbursement • Follow up procedures

  5. Scope of The Services in Regulatory Affairs • Consultation and registration services in the territories • EU countries • Russia • Ukraine • Strategy, Registration, Maintenance Services in • Human and veterinary medicinal products • All alternatives of registration procedures (National, CP, MRP, DCP) • Food supplements and novel foods • Medical equipments/devices • „Health“ cosmetics

  6. Registration Files - Submissions • Compilation and evaluation • Completeness and quality check: pre-submission • PreparationofCTD files • Support in creating Module 1 for all procedures according national/EU requirements • Negotiations with authorities • DCP slots blocking and management • Transforming/ creating ofe-CTD format

  7. e-CTD • The electronic Common Technical Document (e-CTD) is an interface for the pharmaceutical industry to agency transfer of regulatory information. The content is based on the Common Technical Document (CTD) format. • The e-CTD was developed by theICH as standard format for regulatory submissions in the Europe, USA and Japan.

  8. RegistrationFiles - Text Management Compliance in each country • Patient Information Leaflet (PIL), Summary of Product Characteristics (SPC), packaging material (mock-ups) • Harmonization of textsaccording to: • Actual QRD format • Localrequirements • EU reference product (generics) • Mock-up creation • Translation of texts to all languages • Braille requirements The smooth pass of the texts fundamental part of instant national phase of registration

  9. Complex Regulatory Maintenance Management • Variations • Communication with authorities • Renewals of MAs • Sunset clause monitoring and solving Professional maintenance managementsaved time, stress, money…

  10. Pharmacovigilance • Pharmacovigilance monitoring of the products 24/7/365 • Non-stop services for receipt of adverse events signals • Proprietary PHV database • Literature search service • Safety studies /clinical trials support • Complex services of QPPV: • Creation and run of the PHV system according to current EU requirements • Electronic submission of ADRs/AEs to EMA/NA (MedDRA, EudraVig) • Compulsory regular PHV training of the staff • Electronic submission of product information to EMA database (XEVMPD)

  11. OtherServices • Public information service • 24/7/365 patient service • Disabled people • Consultation services for • Patients • Health care professionals • Companies The role of pharmacovigilance is becoming extremely important part of the dailybusiness

  12. ClinicalTrials

  13. Clinical Trial Preparation • Feasibility studies, start-up support • Selection of qualified investigators and trial sites • Preparation of study documents (Protocol, Investigator´s Brochure, Informed Consent Form, questionnaires, manuals etc.) • Protocol and medical writing • Statistical support, clinical trial designing • Submission to regulatory authorities and ethics committees • Co-ordination of preparation works, investigator´s meeting

  14. Monitoring and CT Management • Site management, communication with investigators, on-site activities • Trial monitoring in compliance with Good Clinical Practice (GCP) • Data management and statistical data processing • Identification of changes and evaluation of regulatory aspects • Supervisionof the progress of a clinical trial • Supportfor fast recruitment • Ensuring protocol compliance • Applying SOPs, GCP and applicable regulatory requirements • Setup of adequate procedures for quality control and quality assurance

  15. MedicalServices Support of the investigators • Preparation of Standard Operating Procedures • Good Clinical Practice trainings • Good Laboratory Practice trainings • Good Manufacturing Practice for Advanced Therapies • Legal aspects of CT, data protection, insurance Medical Services • Medical support of project teams • 24/7 medical support, ongoing medical safety review • Medical review of clinical study reports • Medical expert opinion • Medical reporting (interim, final reports, safety reports)

  16. Pharmacovigilance , Risk Management • QPPV service • Immediate report of serious adverse events to sponsor • Reporting of SUSARS and all safety issues tocompetentauthority and ethics committee • Submission of annual safety reports to competent authority and ethics committee • Transmission of safety reports to investigators • Immediate hazard management • Risk management plan • Continuous follow-up and evaluation of risks • Quality assurance and Quality Control, QA/QC Audits

  17. PASS

  18. Post-AuthorisationSafetyStudies (PASS) • A post-authorisationsafety study (PASS) isdefined in Article 1(15) of Directive 2001/83/ECas any study relating to anauthorisedmedicinalproductconductedwiththeaim of identifying, characterisingorquantifying a safety hazard, confirmingthesafety profile of themedicinalproduct, or of measuringtheeffectiveness of risk-management measures. • PASS are designed to ensurethatmedicinalproducts are monitoredforlong-term safetyandeffectiveness in RoutineClinicalPracticeandmaybeinitiated, managedorfinanced by MAH voluntarily, orpursuant to anobligationimposed by a competentauthority. • PASS – Critical New Tool in searchingfor „MissingInformation“

  19. PASS - Services PASS Management • Definitionofscientificformat of protocols, abstractsandfinal study report for non-interventional PASS • IdentificationoftheRequirementsandKeyelementsfor PASS • CreatingGuidance on Effectiveness of Risk Minimisation • Establishing monitoring system – GVP (Good Pharmacovigilance Practice) • E-register of non-interventional PASS maintained by theAgency • Publication of Final Study Report PASS On-siteservices • ON-SITE preparation of PASS (including on-sitetraining, contractissueetc.) • ON-SITE Data Management and Data Collection of PASS • e-CRFsservices, Statisticalanalysis • Preparing FINAL Study Report

  20. Education & Training

  21. Education & Training Regulatory affairs excellence ismainlydriven by knowledge – let´s beup to dateandlearneffectively • Life Cycle of Medicinal Products • Biostatistics • GCP course • Coordination of the clinical trials Allcourses are provided in co-operationwith PharmAroundeducationplatform www.pharmaround.com

  22. Marketing + Sales

  23. Market Access • Market analysis and market environment • Market Access strategy – reflecting actual and upcoming legislation development and „current“ practices • Pharmacoeconomic analysis • Budget impact • Cost effectiveness • Cost containment….. • Preparation and submission of application for • Maximum price • Reimbursement • Organisation of „patient registries“ • Management of„life cycle“ of the reimbursement/price

  24. Knowledge - Creativity - Dedication - Success Committed to Your Success Slunná 16, Brno, 617 00CzechRepublic www.asamuel.eue-mail: office@asamuel.eutelefon: +420 534 008 052Fax: +420 545 233 606

More Related